187 related articles for article (PubMed ID: 35935979)
21. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
Front Immunol; 2021; 12():693062. PubMed ID: 34497605
[TBL] [Abstract][Full Text] [Related]
22. A Multi-Omics Study on the Effect of Helicobacter Pylori-Related Genes in the Tumor Immunity on Stomach Adenocarcinoma.
Wu X; Jian A; Tang H; Liu W; Liu F; Liu S; Wu H
Front Cell Infect Microbiol; 2022; 12():880636. PubMed ID: 35619651
[TBL] [Abstract][Full Text] [Related]
23. Identification of RFX5 as prognostic biomarker and associated with immune infiltration in stomach adenocarcinoma.
Guo L; Liu D
Eur J Med Res; 2022 Aug; 27(1):164. PubMed ID: 36045400
[TBL] [Abstract][Full Text] [Related]
24. Identification of a Costimulatory Molecule-Related Signature for Predicting Prognostic Risk in Prostate Cancer.
Ge S; Hua X; Chen J; Xiao H; Zhang L; Zhou J; Liang C; Tai S
Front Genet; 2021; 12():666300. PubMed ID: 34484286
[TBL] [Abstract][Full Text] [Related]
25. Identification and Construction of a Long Noncoding RNA Prognostic Risk Model for Stomach Adenocarcinoma Patients.
Zha Z; Zhang P; Li D; Liu G; Lu L
Dis Markers; 2021; 2021():8895723. PubMed ID: 33680217
[TBL] [Abstract][Full Text] [Related]
26. Comprehensive analysis of the immune and prognostic implication of MASP1 in stomach adenocarcinoma.
Zhang CH; Xu ZQ; Peng LL; Wang JJ; Gu HT
Eur Rev Med Pharmacol Sci; 2022 Sep; 26(18):6725-6741. PubMed ID: 36196721
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive Characterization of Transforming Growth Factor Beta Receptor 1 in Stomach Adenocarcinoma Identifies a Prognostic Signature for Predicting Clinical Outcomes and Immune Infiltrates.
He Y; Zhang H; Zhang Y; Wang P; Zhu K; Ba Y
Int J Gen Med; 2022; 15():3375-3391. PubMed ID: 35368798
[TBL] [Abstract][Full Text] [Related]
28. Identification and validation of a novel prognostic circadian rhythm-related gene signature for stomach adenocarcinoma.
Qian L; Ding X; Fan X; Li S; Qiao Y; Zhang X; Li J
Chronobiol Int; 2023 Jun; 40(6):744-758. PubMed ID: 37122167
[TBL] [Abstract][Full Text] [Related]
29. A Necroptosis-Related lncRNA-Based Signature to Predict Prognosis and Probe Molecular Characteristics of Stomach Adenocarcinoma.
Luo L; Li L; Liu L; Feng Z; Zeng Q; Shu X; Cao Y; Li Z
Front Genet; 2022; 13():833928. PubMed ID: 35330731
[No Abstract] [Full Text] [Related]
30. Identification and characterization of nucleotide metabolism and neuroendocrine regulation-associated modification patterns in stomach adenocarcinoma with auxiliary prognostic assessment and immunotherapy response prediction.
Zhang Y; Zeng L; Lin D; Chang G; Zeng Y; Xia Y
Front Endocrinol (Lausanne); 2022; 13():1076521. PubMed ID: 36726460
[TBL] [Abstract][Full Text] [Related]
31. A novel immune checkpoint-related seven-gene signature for predicting prognosis and immunotherapy response in melanoma.
Tian M; Yang J; Han J; He J; Liao W
Int Immunopharmacol; 2020 Oct; 87():106821. PubMed ID: 32731180
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive Analysis of the Immune Implication of AKAP12 in Stomach Adenocarcinoma.
Xu Z; Xiang L; Peng L; Gu H; Wang Y
Comput Math Methods Med; 2022; 2022():3445230. PubMed ID: 36148016
[TBL] [Abstract][Full Text] [Related]
33. Protein-based prognostic signature for predicting the survival and immunotherapeutic efficiency of endometrial carcinoma.
Lai J; Xu T; Yang H
BMC Cancer; 2022 Mar; 22(1):325. PubMed ID: 35337291
[TBL] [Abstract][Full Text] [Related]
34. Sarcopenia and a 5-mRNA risk module as a combined factor to predict prognosis for patients with stomach adenocarcinoma.
Yang H; Tian W; Zhou B
Genomics; 2022 Jan; 114(1):361-377. PubMed ID: 34933074
[TBL] [Abstract][Full Text] [Related]
35. Increased ANXA5 expression in stomach adenocarcinoma infers a poor prognosis and high level of immune infiltration.
Su Z; Shu K; Li G
Cancer Biomark; 2022; 35(2):155-165. PubMed ID: 35912732
[TBL] [Abstract][Full Text] [Related]
36. A signature of 14 immune-related gene pairs predicts overall survival in gastric cancer.
Zhao E; Zhou C; Chen S
Clin Transl Oncol; 2021 Feb; 23(2):265-274. PubMed ID: 32519178
[TBL] [Abstract][Full Text] [Related]
37. Comprehensive analysis to identify DNA damage response-related lncRNA pairs as a prognostic and therapeutic biomarker in gastric cancer.
Yang Y; Zhou L; Gou X; Wu G; Zheng Y; Liu M; Chen Z; Wang Y; Ji R; Guo Q; Zhou Y
Math Biosci Eng; 2022 Jan; 19(1):595-611. PubMed ID: 34903003
[TBL] [Abstract][Full Text] [Related]
38. Immune Infiltration Subtypes Characterization and Identification of Prognosis-Related lncRNAs in Adenocarcinoma of the Esophagogastric Junction.
Hu X; Wu L; Liu B; Chen K
Front Immunol; 2021; 12():651056. PubMed ID: 34122409
[TBL] [Abstract][Full Text] [Related]
39. Identification of prognosis-related genes in the tumor microenvironment of stomach adenocarcinoma by TCGA and GEO datasets.
Ren N; Liang B; Li Y
Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 33015704
[TBL] [Abstract][Full Text] [Related]
40. Multi-omics profiling and digital image analysis reveal the potential prognostic and immunotherapeutic properties of CD93 in stomach adenocarcinoma.
Wu B; Fu L; Guo X; Hu H; Li Y; Shi Y; Zhang Y; Han S; Lv C; Tian Y
Front Immunol; 2023; 14():984816. PubMed ID: 36761750
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
